20946663|t|Treatment combining RU486 and Ad5IL-12 vector attenuates the growth of experimentally formed prostate tumors and induces changes in the sentinel lymph nodes of mice.
20946663|a|BACKGROUND: Tumor immune responses are first generated and metastases often begin in tumor sentinel lymph nodes (TSLN). Therefore, it is important to promote tumor immunity within this microenvironment. Mifepristone (RU486) treatment can interfere with cortisol signaling that can lead to suppression of tumor immunity. Here, we assessed whether treatment with RU486 in conjunction with an intratumor injection of Ad5IL-12 vector (a recombinant adenovirus expressing IL-12) could impact the TSLN microenvironment and prostate cancer progression. METHODS: The human PC3, LNCaP or murine TRAMP-C1 prostate cancer cell lines were used to generate subcutaneous tumors in NOD.scid and C57BL/6 mice, respectively. Adjuvant effects of RU486 were looked for in combination therapy with intratumor injections (IT) of Ad5IL-12 vector in comparison to PBS, DL70-3 vector, DL70-3 + RU486, RU486 and Ad5IL-12 vector treatment controls. Changes in tumor growth, cell cytotoxic activity and populations of CD4+/FoxP3+ T regulatory cells (Treg) in the TSLN were evaluated. RESULTS: Treatment of human PC3 prostate xenograft or TRAMP-C1 tumors with combination Ad5IL-12 vector and RU486 produced significantly better therapeutic efficacy in comparison to controls. In addition, we found that combination therapy increased the capacity of TSLN lymphocytes to produce Granzyme B in response to tumor cell targets. Finally, combination therapy tended towards decreases of CD4+/FoxP3+ T regulatory cell populations to be found in the TSLN. CONCLUSION: Inclusion of RU486 may serve as a useful adjuvant when combined with proinflammatory tumor killing agents by enhancement of the immune response and alteration of the TSLN microenvironment.
20946663	20	25	RU486	Chemical	MESH:D015735
20946663	93	108	prostate tumors	Disease	MESH:D011472
20946663	160	164	mice	Species	10090
20946663	178	183	Tumor	Disease	MESH:D009369
20946663	225	235	metastases	Disease	MESH:D009362
20946663	251	256	tumor	Disease	MESH:D009369
20946663	324	329	tumor	Disease	MESH:D009369
20946663	369	381	Mifepristone	Chemical	MESH:D015735
20946663	383	388	RU486	Chemical	MESH:D015735
20946663	419	427	cortisol	Chemical	MESH:D006854
20946663	470	475	tumor	Disease	MESH:D009369
20946663	527	532	RU486	Chemical	MESH:D015735
20946663	611	621	adenovirus	Species	10508
20946663	683	698	prostate cancer	Disease	MESH:D011471
20946663	725	730	human	Species	9606
20946663	731	734	PC3	CellLine	CVCL:0035
20946663	736	741	LNCaP	CellLine	CVCL:0395
20946663	745	751	murine	Species	10090
20946663	752	760	TRAMP-C1	CellLine	CVCL:H593
20946663	761	776	prostate cancer	Disease	MESH:D011471
20946663	810	829	subcutaneous tumors	Disease	MESH:D009369
20946663	851	853	/6	CellLine	CVCL:5985
20946663	854	858	mice	Species	10090
20946663	894	899	RU486	Chemical	MESH:D015735
20946663	1012	1018	DL70-3	CellLine	CVCL:J397
20946663	1027	1033	DL70-3	CellLine	CVCL:J397
20946663	1036	1041	RU486	Chemical	MESH:D015735
20946663	1043	1048	RU486	Chemical	MESH:D015735
20946663	1100	1105	tumor	Disease	MESH:D009369
20946663	1157	1160	CD4	Gene	920
20946663	1162	1167	FoxP3	Gene	20371
20946663	1245	1250	human	Species	9606
20946663	1251	1254	PC3	CellLine	CVCL:0035
20946663	1255	1263	prostate	Disease	MESH:D011472
20946663	1277	1285	TRAMP-C1	CellLine	CVCL:H593
20946663	1286	1292	tumors	Disease	MESH:D009369
20946663	1330	1335	RU486	Chemical	MESH:D015735
20946663	1515	1525	Granzyme B	Gene	3002
20946663	1541	1546	tumor	Disease	MESH:D009369
20946663	1618	1621	CD4	Gene	12504
20946663	1623	1628	FoxP3	Gene	20371
20946663	1710	1715	RU486	Chemical	MESH:D015735
20946663	1766	1781	proinflammatory	Disease	
20946663	1782	1787	tumor	Disease	MESH:D009369
20946663	Negative_Correlation	MESH:D015735	MESH:D011471
20946663	Negative_Correlation	MESH:D015735	MESH:D011472
20946663	Negative_Correlation	MESH:D015735	MESH:D009369
20946663	Association	MESH:D006854	MESH:D015735
20946663	Association	MESH:D009369	3002

